Back In Fashion? Boston’s CBO Talks Turkey On Reinvigorating Pharma’s Unwanted Assets
Constantine Chinoporos, Boston Pharmaceuticals’ CBO, talks to Scrip about its deal strategy and how it intends to build its pipeline over the next few years, liberated from the constraints of portfolio management.
You may also be interested in...
The US firm is getting its hands on eight programs from two of the world's leading drug makers, seeing an opportunity in areas such as antibiotics where solutions may be more likely to come from biotech rather than big pharma.
With their first collaboration producing the potential blockbuster Praluent and other near-market medicines, Sanofi and Regeneron are likely hoping they can repeat the trick with a new $2bn-deal covering immune-oncology.
In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.